Zentalis Pharmaceuticals ZNTL Cash Flow Statement (2019-2026)

NASDAQ ZNTL
$2.39 +0.09 (+3.91%)
At close: Oct 20, 2026 · 4:00 PM EDT
Reported Financials

Zentalis Pharmaceuticals Quarterly Cash Flow Statement

Periods 30 quarters
Latest Jun 2026

Zentalis Pharmaceuticals reported cash from operations of -$37.24M and free cash flow of -$37.24M for the quarter ended Jun 2026, down 7.3% year over year. This cash flow statement covers 30 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-10.49M-50.10M-59.24M-68.39M-54.50M-54.98M-63.26M-112.56M-55.54M-60.94M10.07M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M-42.29M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.14M0.21M0.34M0.35M0.38M0.33M0.36M0.34M0.35M0.30M0.32M0.33M0.32M0.33M0.26M0.16M0.16M0.16M0.15M0.15M
Share-based CompensationStock Comp.
7.66M8.47M10.15M16.76M10.32M9.61M13.73M13.34M13.87M13.88M12.83M12.71M10.36M31.36M6.49M6.29M4.83M3.12M3.20M3.22M
Deferred Taxes
-0.07M0.07M-0.77M-0.10M-0.76M
Gains from Equity InvestmentsGains Equity
-1.83M-1.75M-5.34M-2.37M-6.82M-2.31M-13.70M
Gains from Sales and DivestituresGains Divest
-0.06M0.13M-0.12M0.00M-0.41M0.07M-0.05M0.53M0.10M0.03M
Gains from Investment SecuritiesGains Investment
31.17M-28.92M5.67M-2.69M-7.02M4.64M3.47M0.15M
Asset Writedowns and ImpairmentWritedown
4.95M3.70M1.15M2.98M
Other non-cash itemsOther Non-Cash
0.19M0.20M0.15M-0.13M
Change in Working Capital
15.53M-13.33M7.26M7.08M-1.75M8.33M1.17M1.38M0.73M-1.73M
Change in ReceivablesChange Receivables
0.10M-0.10M0.00M5.00M-5.00M
Change in Accured ExpensesChange Accured Exp.
7.47M1.65M-0.50M4.53M6.45M5.05M-1.41M-4.39M6.33M10.40M-15.25M11.80M-12.01M-2.56M-4.02M-10.58M-1.98M-0.73M-1.45M2.26M
Change in Other Operating AssetsOther Assets Change
-5.22M0.40M4.15M2.51M-1.95M1.89M2.92M1.01M1.28M0.48M1.06M-1.61M-5.44M-0.23M-0.66M-2.35M-0.68M0.70M-0.97M0.37M
Other Working Capital ChangesOther WC Changes
0.39M-1.47M-1.38M-0.90M-1.23M-0.82M-0.31M-0.24M0.27M-0.35M-0.77M0.08M0.69M-0.26M-0.11M0.09M-0.13M-0.05M0.25M0.16M
Cash from OperationsCash from Ops.
-33.49M-37.02M-50.20M-43.03M-33.20M-37.33M-49.28M-79.28M-38.67M-40.60M-51.97M-35.14M-44.05M-39.70M-32.64M-34.71M-26.96M-30.94M-32.96M-37.24M
Investing Activities
Capital ExpendituresCapex
2.66M2.19M0.45M0.28M1.66M0.16M0.32M0.09M0.17M0.04M0.18M0.03M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.07M0.01M0.56M0.13M
Change in Property, Plant and EquipmentChange in PP&E
-2.66M-2.19M-0.45M-0.28M-1.66M-0.16M-0.32M-0.09M-0.17M-0.04M-0.12M0.01M0.56M0.13M-0.03M
Purchase of InvestmentsInvestments Purchased
202.47M83.22M79.25M198.32M129.60M125.98M63.88M125.21M264.11M95.99M10.12M19.39M59.24M39.22M19.53M40.19M49.53M30.24M29.95M29.98M
Sale and Maturity of InvestmentsInvestments Sold
78.01M128.68M99.50M56.50M151.28M114.25M106.00M198.46M146.75M54.10M71.70M54.00M74.00M71.50M60.00M70.00M60.00M62.56M60.00M60.00M
Cash from Investing ActivitiesCash from Investing
-141.44M43.27M19.80M-142.10M20.02M-11.89M42.12M72.93M-117.45M-42.06M61.55M34.49M48.24M32.28M40.48M30.38M28.32M32.45M30.01M30.02M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
166.18M13.41M1.26M209.46M0.59M49.74M0.37M236.62M0.31M0.25M0.01M0.09M0.19M0.12M5.39M0.33M0.07M
Net Shares Issued and RepurchasedNet Shares Issued
166.18M13.41M1.26M209.46M0.59M49.74M0.37M236.62M0.31M0.25M0.01M0.09M0.19M0.12M5.39M0.33M0.07M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
166.18M13.41M1.26M209.46M0.59M49.74M0.37M236.62M0.31M0.25M0.01M0.09M0.19M0.12M5.39M0.33M0.07M
Other financing activitiesOther financing
0.39M-0.24M
Cash from Financing ActivitiesCash from Financing
166.57M12.27M1.26M209.46M0.59M49.74M0.37M236.62M0.31M0.01M0.01M0.09M0.19M0.12M-4.59M-1.12M0.07M
Additional items
Change in Cash
-8.36M18.51M-29.14M24.33M-12.59M0.52M-6.79M230.28M-155.81M-82.66M9.58M-0.64M4.29M-7.42M8.03M-4.33M1.47M-3.08M-4.07M-7.15M
Ending Cash Balance
44.07M62.58M33.44M57.77M45.18M45.70M38.91M269.19M113.38M30.72M40.30M39.66M43.95M36.53M44.56M40.23M41.70M38.62M34.56M27.41M
Free Cash FlowFCF
-36.15M-39.21M-50.65M-43.31M-34.86M-37.49M-49.28M-79.59M-38.76M-40.77M-52.01M-35.32M-44.05M-39.70M-32.64M-34.71M-26.96M-30.94M-32.99M-37.24M
Net Cash FlowNCF
-8.36M18.51M-29.14M24.33M-12.59M0.52M-6.79M230.28M-155.81M-82.66M9.58M-0.64M4.29M-7.42M8.03M-4.33M1.47M-3.08M-4.07M-7.15M

Zentalis Pharmaceuticals Cash Flow Statement API

Pull Zentalis Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ZNTL&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY